Adjuvant therapy of melanoma: is pegylated interferon alfa-2b what we've been waiting for?

Lancet. 2008 Jul 12;372(9633):89-90. doi: 10.1016/S0140-6736(08)61011-9.
No abstract available

Publication types

  • Comment

MeSH terms

  • Antiviral Agents / adverse effects
  • Antiviral Agents / pharmacokinetics
  • Antiviral Agents / therapeutic use*
  • Chemotherapy, Adjuvant
  • Disease-Free Survival
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / adverse effects
  • Interferon-alpha / pharmacokinetics
  • Interferon-alpha / therapeutic use*
  • Melanoma / drug therapy*
  • Melanoma / pathology
  • Polyethylene Glycols
  • Randomized Controlled Trials as Topic
  • Recombinant Proteins
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / pathology

Substances

  • Antiviral Agents
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Polyethylene Glycols
  • peginterferon alfa-2b